2,2-Di(propan-2-yl)pentanal

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机氧化物
• 英文名称: 2,2-Di(propan-2-yl)pentanal
• 英文别名: 2,2-di(propan-2-yl)pentanal
• 化学式: C₁₁H₂₂O
• 分子量: 170.29
• InChiKey: CEICKWSFPAEFCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• USE OF DERIVATIVES WITH C-O-P BONDS IN PATIENTS WITH RENAL FAILURE
  申请人：Laboratorios Sanifit, S.L.

  公开号：EP2974714A1

  公开（公告）日：2016-01-20

  The invention relates to the use of a derivative with C-O-P bonds in the form of controlled release for the treatment of patients with renal failure. The invention also relates to the use of said derived compounds together with other active substances, that can particularly be selected from the list comprising a calcimimetic, a vitamin, a phosphorus chelator, thiosulfate, biphosphonate, pyrophosphate, citrate, a diuretic, an antihypertensive and an anticholesterolemic agent.

  本发明涉及以控释形式使用具有 C-O-P 键的衍生物来治疗肾衰竭患者。本发明还涉及上述衍生化合物与其他活性物质一起使用的问题，这些活性物质尤其可以从包括降钙剂、维生素、磷螯合剂、硫代硫酸盐、双磷酸盐、焦磷酸盐、柠檬酸盐、利尿剂、抗高血压剂和抗胆固醇剂在内的清单中选择。
• INOSITOL PHOSPHATE COMPOUNDS FOR USE IN TREATING, INHIBITING THE PROGRESSION, OR PREVENTING CARDIOVASCULAR CALCIFICATION
  申请人：Sanifit Therapeutics S.A.

  公开号：EP3818983A1

  公开（公告）日：2021-05-12

  The present invention relates to compounds, pharmaceutical compositions, combined preparations, and dosage regimens for treating, inhibiting the progression, and preventing cardiovascular calcification, and in particular, coronary calcification, aortic artery calcification, and aortic valve calcification comprising inositol phosphates. In a particular aspect the disclosure provides a dosage regimen for treating, inhibiting the progression, or preventing cardiovascular calcification comprising the administration of about 200 mg to about 700 mg of myo-inositol hexaphosphate per administration.

  本发明涉及用于治疗、抑制进展和预防心血管钙化，特别是冠状动脉钙化、主动脉钙化和主动脉瓣钙化的包含肌醇磷酸盐的化合物、药物组合物、联合制剂和剂量方案。在一个特定方面，本公开提供了一种治疗、抑制进展或预防心血管钙化的剂量方案，包括每次给药约200毫克至约700毫克肌醇六磷酸酯。
• PROCESSES FOR THE PREPARATION OF SOLUBLE SALTS OF INOSITOL PHOSPHATES
  申请人：Sanifit Therapeutics S.A.

  公开号：EP4015494A1

  公开（公告）日：2022-06-22

  The present invention provides processes for preparing soluble salts of inositol phosphate characterized by a low level of impurities. Processes for preparing soluble salts (e.g., alkali-metal or ammonium) of inositol phosphates (e.g., hexasodium or dodecasodium salts), and of inositol hexaphosphate in particular (e.g., Na6IP6 and Na12IP6), are described. Also provided are pharmaceutical compositions, methods of use, combination treatments, kits, and articles of manufacture comprising soluble salts of inositol phosphates prepared according to the method of the invention.

  本发明提供了以杂质含量低为特征的磷酸肌醇可溶性盐的制备工艺。本发明描述了制备肌醇磷酸盐（如六钠盐或十二钠盐），特别是肌醇六磷酸酯（如 Na6IP6 和 Na12IP6）的可溶性盐（如碱金属盐或铵）的工艺。还提供了药物组合物、使用方法、组合治疗、试剂盒和制造品，其中包含根据本发明方法制备的肌醇磷酸盐的可溶性盐。
• Use of derivatives containing C-O-P bonds in patients with kidney failure
  申请人：LABORATORIOS SANIFIT, S.L.

  公开号：US10010559B2

  公开（公告）日：2018-07-03

  Use of a derivative containing C—O—P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.

  将含有 C-O-P 键的衍生物以控释形式用于治疗肾衰竭患者。此外，它还包括将上述衍生物与其他活性物质一起使用，这些活性物质尤其可以从包括降钙剂、维生素、磷酸盐粘合剂、硫代硫酸盐、双磷酸盐、焦磷酸盐、枸橼酸盐、利尿剂、降压药和抗胆碱酯酶药在内的列表中选出。
• IP and IP analogs dosage regimens for the treatment of ectopic calcifications
  申请人：SANIFIT THERAPEUTICS S.A.

  公开号：US10973838B2

  公开（公告）日：2021-04-13

  The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.

  本公开涉及用于治疗和/或预防异位钙化，特别是皮肤钙化，如钙化性钙化的组合物、方法、剂量、剂量方案、制造品和试剂盒，包括磷酸肌醇、磷酸肌醇类似物、磷酸肌醇衍生物或其组合。在一个特定方面，本公开提供了一种治疗钙化症的剂量方案，包括每天服用6毫克/千克至9毫克/千克的肌醇六磷酸酯，每周三次，持续至少1至8个月。